STOCK TITAN
  1. Home
  2. News
  3. OCUL

Ocular Therapeutix, Inc. - OCUL STOCK NEWS

Welcome to our dedicated page for Ocular Therapeutix news (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeutix stock.

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company dedicated to enhancing vision and quality of life through the development, manufacturing, and commercialization of innovative ocular therapies. The company employs its proprietary hydrogel-based formulation technology to address various diseases and conditions affecting the eye.

The company's lead product, DEXTENZA® (dexamethasone insert), an FDA-approved corticosteroid, is designed for intracanalicular use to treat ocular inflammation and pain following ophthalmic surgery and ocular itching due to allergic conjunctivitis. DEXTENZA delivers dexamethasone to the ocular surface for up to 30 days without preservatives, resorbing naturally, eliminating the need for removal.

Ocular Therapeutix’s pipeline includes several promising candidates. OTX-TIC (travoprost intracameral implant) is in Phase 2 trials for treating open-angle glaucoma and ocular hypertension. Another key candidate is AXPAXLI™ (axitinib intravitreal implant), currently in Phase 3 trials for wet age-related macular degeneration (AMD) and Phase 1 trials for non-proliferative diabetic retinopathy (DR). The company also has OTX-CSI (cyclosporine intracanalicular insert) and OTX-DED (dexamethasone intracanalicular insert) for dry eye disease.

Recently, Ocular Therapeutix announced positive Phase 1 results for AXPAXLI in diabetic retinopathy, accelerating its development to Phase 3. Moreover, recent strategic changes include the appointment of Dr. Pravin U. Dugel as the CEO, aiming to transform the company into a leading retina-focused biopharmaceutical entity.

Ocular Therapeutix has secured significant partnerships and funding to support the clinical development of its robust pipeline. These include a licensing agreement with AffaMed Therapeutics for the commercialization of DEXTENZA in Greater China and ASEAN markets.

Follow Ocular Therapeutix for the latest updates on their innovative pipeline and corporate developments via their website, LinkedIn, and Twitter.

News

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

Rhea-AI Summary
Ocular Therapeutix™ announces positive topline Phase 1 data for AXPAXLI™ in diabetic retinopathy, with 46.2% of patients showing improvement in the Diabetic Retinopathy Severity Scale at 40 weeks. AXPAXLI was well-tolerated with no inflammation observed. The company plans to move directly to a Phase 3 study based on the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.69%
Tags
clinical trial
-
News

Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

Rhea-AI Summary
Ocular Therapeutix strengthens its clinical team by appointing key retinal leaders, including Dr. Nadia K. Waheed as Chief Medical Officer and Dr. Peter K. Kaiser as Chief Development Officer. The company aims to advance its Phase 3 AXPAXLI program for wet AMD and diabetic retinopathy, positioning itself as a leading retina care company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
management
-
News

Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO

Rhea-AI Summary
Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced that Executive Chairman, Pravin U. Dugel, MD, is taking over as President and CEO, with Antony Mattessich stepping down. Dr. Dugel will also continue as a director and Executive Chairman. The company expressed gratitude for Mattessich's service and highlighted the potential of their innovative retinal disease pipeline, particularly AXPAXLI™.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
none
News

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics

Rhea-AI Summary
Ocular Therapeutix, Inc. (OCUL) granted inducement equity awards to its new Senior Vice President, Global Head of Biometrics. The awards include a stock option for 130,000 shares and a restricted stock unit award for 43,333 shares. The awards are part of Ocular's 2019 Inducement Stock Incentive Plan and are subject to specific vesting schedules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
none
-
News

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

Rhea-AI Summary
Ocular Therapeutix, Inc. announces positive Phase 2 data for PAXTRAVA implant in patients with open-angle glaucoma or ocular hypertension. The data show consistent and sustained reductions in Intraocular Pressure (IOP) over six months, with a 24-30% reduction achieved. The implant was well-tolerated, with no impact on corneal health observed. The results indicate potential for repeat dosing without stacking of implants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)

Rhea-AI Summary
Ocular Therapeutix, Inc. announces multiple scientific presentations at the 2024 ASCRS Annual Meeting. The presentations focus on innovative therapies for eye diseases like wet AMD and diabetic retinopathy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
conferences
News

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results

Rhea-AI Summary
Ocular Therapeutix, Inc. reports financial results, leadership appointments, and upcoming milestones. The company aims to be a leader in retinal care with a focus on wet AMD, diabetic retinopathy, and glaucoma treatments. Positive milestones include successful financings, key leadership appointments, and progress in clinical trials. Financially, the company has a strong cash position and increasing revenues. However, there are concerns regarding rising research and development expenses, net losses, and non-cash charges.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.52%
Tags
earnings
-
News

Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024

Rhea-AI Summary
Ocular Therapeutix, Inc. (OCUL) plans to report its fourth quarter and full year 2023 financial results on March 11, 2024, after 4:00 p.m. Eastern Time. The company will not host a conference call due to recent leadership appointments and a $325 million private placement. A conference call to discuss corporate strategy is scheduled for the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
earnings
-
News

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer

Rhea-AI Summary
Ocular Therapeutix, Inc. (OCUL) grants inducement equity awards to Executive Chairman and Chief Strategy Officer, Dr. Pravin U. Dugel and Dr. Sanjay Nayak. The awards include stock options and restricted stock units, with vesting schedules over multiple years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.99%
Tags
none
News

Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement

Rhea-AI Summary
Ocular Therapeutix, Inc. announces a private placement to raise $325.0 million through the sale of common stock and pre-funded warrants to institutional accredited investors. The funds will be used to accelerate the clinical development of AXPAXLI™ for wet AMD treatment, support other clinical programs, and for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.99%
Tags
none

FAQ

What is the current stock price of Ocular Therapeutix (OCUL)?

The current stock price of Ocular Therapeutix (OCUL) is $8.76 as of January 3, 2025.

What is the market cap of Ocular Therapeutix (OCUL)?

The market cap of Ocular Therapeutix (OCUL) is approximately 1.4B.

What is Ocular Therapeutix’s main technology platform?

Ocular Therapeutix uses a proprietary hydrogel-based formulation technology for delivering therapeutic agents to the eye.

What is DEXTENZA® used for?

DEXTENZA® is used for treating ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis.

Which product is Ocular Therapeutix developing for open-angle glaucoma?

Ocular Therapeutix is developing OTX-TIC (travoprost intracameral implant) for the treatment of open-angle glaucoma and ocular hypertension.

What is the status of AXPAXLI™ (OTX-TKI)?

AXPAXLI™ (OTX-TKI) is currently in Phase 3 clinical trials for wet AMD and Phase 1 trials for non-proliferative diabetic retinopathy.

Who is the current CEO of Ocular Therapeutix?

Dr. Pravin U. Dugel is the current President and CEO of Ocular Therapeutix.

What recent partnerships has Ocular Therapeutix secured?

Ocular Therapeutix has a licensing agreement with AffaMed Therapeutics for the commercialization of DEXTENZA in Greater China and ASEAN markets.

What are OTX-CSI and OTX-DED?

OTX-CSI is a cyclosporine intracanalicular insert for the chronic treatment of dry eye disease. OTX-DED is a dexamethasone intracanalicular insert for the short-term treatment of dry eye symptoms.

How long does DEXTENZA deliver medication?

DEXTENZA delivers dexamethasone to the ocular surface for up to 30 days without the need for preservatives or removal.

What clinical trial results were recently announced for AXPAXLI?

Ocular Therapeutix announced positive topline results from the Phase 1 HELIOS study for AXPAXLI in non-proliferative diabetic retinopathy.

What is the focus of Ocular Therapeutix?

Ocular Therapeutix focuses on developing innovative therapies for ocular diseases, including wet AMD, diabetic retinopathy, open-angle glaucoma, and dry eye disease.
Stock OCUL logo
Ocular Therapeutix, Inc.

Nasdaq:OCUL

OCUL Rankings

#2263 Ranked by Market Cap
N/A Ranked by Dividends

OCUL Stock Data

1.40B
151.33M
1.06%
91.08%
8.13%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BEDFORD